title: Interleukin 2 as a potential cancer marker in patients after kidney transplantation.
abstract: BACKGROUND
  Transplant recipients have a significantly greater incidence of cancer, compared with the general population, who are referred to immunosuppressive therapy as an additional malignancy risk factor. Therefore, there is a need to search for an easy in clinical practice neoplasm predictor, especially for this group of patients.
  
  
  METHODS
  A group of 74 (43M and 31F; aged 46.8 ± 12 years) kidney transplant recipients was investigated in a three-year follow-up study. During the time of observation, 7 patients were diagnosed with neoplasm (7.4 ± 1.5 years after transplantation). A serum level of IL2 (ELISA test) and mRNA level of IL1beta, IL10 and TNFalfa in peripheral mononuclear blood cells - PBMCs (QRT - PCR method) were measured in every year of observation. Analysis of variances and t-Student test were used in groups mean comparison: N - patients developing malignant neoplasm group (24 probes); M - set of probes from patients with malignancies at the moment of diagnosis (11 probes); P - set of probes from patients before developing malignant neoplasm (10 probes); C - control group of healthy transplant recipients (31 probes).
  
  
  RESULTS
  Among the analyzed agents, only serum IL2 level differed between the analyzed groups, with higher values in the M compared with the P group (p<0.05) and with C group (p<0.01). There were no differences neither between N and C or P and C groups (p = 0.98), nor any correlation between IL2 and IL1b, IL2 and TNFalfa.
  
  
  CONCLUSIONS
  The results may indicate that IL2 serum level might be consider as a useful late unspecific cancer marker, although larger studies should yield verification of this finding.
authors.affiliation: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Witkowska
authors.affiliation: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Zywiec
authors.affiliation: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Strozik
authors.affiliation: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
authors.forename: Sylwia
authors.initials: S
authors.lastname: Gorczynska-Kosiorz
authors.affiliation: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
authors.forename: Wanda
authors.initials: W
authors.lastname: Trautsolt
authors.affiliation: Department of Molecular Biology, Medical University of Silesia, Sosnowiec, Poland.
authors.forename: Barbara
authors.initials: B
authors.lastname: Strzalka-Mrozik
authors.affiliation: Department of Molecular Biology, Medical University of Silesia, Sosnowiec, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Kimsa
authors.affiliation: Division of Statistics, Medical University of Silesia, Sosnowiec, Poland.
authors.forename: Aleksander
authors.initials: A
authors.lastname: Owczarek
authors.affiliation: Internal Practice, Bytom, Poland.
authors.forename: Beata
authors.initials: B
authors.lastname: Stępień
authors.affiliation: Department of Molecular Biology, Medical University of Silesia, Sosnowiec, Poland.
authors.forename: Urszula
authors.initials: U
authors.lastname: Mazurek
authors.affiliation: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
authors.forename: Władysław
authors.initials: W
authors.lastname: Grzeszczak
authors.affiliation: Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland.
authors.forename: Janusz
authors.initials: J
authors.lastname: Gumprecht
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics / Q000378:metabolism; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism; D007376:Interleukin-2 / Q000235:genetics* / Q000378:metabolism; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism*; D011044:Poland; D066027:Transplant Recipients; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism
chemical_list: D015415:Biomarkers; C508609:IL10 protein, human; C508585:IL1B protein, human; C508594:IL2 protein, human; D053583:Interleukin-1beta; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10